DiaSorin S.p.A. · MIL:DIA

DiaSorin — Q3 2026 Earnings Presentation

22 slides from DiaSorin's earnings presentation, Nov 12, 2026

  1. Slide 1: Q3 & 9M 2026 Results

    Q3 & 9M 2026 RESULTS November 12, 2026

  2. Slide 2: Disclaimer

    DISCLAIMER In General. This disclaimer applies to this presentation and any oral No distribution of this Presentation. This Presentation is being furnished to comments of any person presenting it. This document, taken together you solely for your information and may not be reproduced, in whole or in

  3. Slide 3: Forward-Looking Statements

    FORWARD-LOOKING STATEMENTS This document contains forward-looking statements that are based on current expectations, estimates, forecasts and projections about the industries in which Diasorin operates and the beliefs and assumptions of the management of Diasorin. In addition, the management of Dias

  4. Slide 4: Business Highlights

    BUSINESS HIGHLIGHTS 6) Diasorin

  5. Slide 5: Business Highlights

    Business Highlights Jan Feb Mar Apr May Jun Oct Nov 2026 2026 2026 2026 2026 2026 2026 2026 LIAISON LIAISON Parvovirus B19 Delta Hepatitis QuantiFERON- IgM Plus &IgG U.S. Market TB Gold Plus II Plus U.S. Market U.S. Market Authorization Commercial LIAISON PLEX LIAISON PLEX request Launch Gastro- LIA

  6. Slide 6: Financial Highlights

    FINANCIAL HIGHLIGHTS 6) Diasorin

  7. Slide 7: Q3'26 & 9M'26 Revenue Variances at Constant Exchange Rates 2025

    Q3’26 & 9M’26 Revenue Variances at Constant Exchange Rates 2025 Q3’26 Group revenues (figures in €/million) 9M’26 Group revenues (figures in €/million) 45 +19% 130 +5% 9M’26 51 Q3’26 Q3’26 147 308 +11% 9M’26 -1% +3% +8% 910 213 632 +5% +3% Immunodiagnostics Immunodiagnostics Molecular Diagnostics Mo

  8. Slide 8: Q3'26 & 9M'26 Immunodiagnostic Revenue Variances At Constant Exchange Rates 2025

    Q3’26 & 9M’26 Immunodiagnostic Revenue Variances At Constant Exchange Rates 2025 Q3’26 revenues (figures in €/million) 9M’26 revenues (figures in €/million) Base Business (ex-China) in Q3’26: China • Growth accelerating QoQ, in line with expectations, in particular CLIA franchise . • Slightly improv

  9. Slide 9: Q3'26 & 9M'26 Molecular Diagnostic Revenue Variances At Constant Exchange Rates 2025

    Q3’26 & 9M’26 Molecular Diagnostic Revenue Variances At Constant Exchange Rates 2025 Q3’26 revenues (figures in €/million) 9M’26 revenues (figures in €/million) Lowplex Multiplex Lowplex Multiplex Automated multiplexing: LIAISON MDX targeted: • Excellent performance of automated multiplexing driven

  10. Slide 10: Automated Multiplexing: LIAISON PLEX

    Automated Multiplexing: LIAISON PLEX LIAISON PLEX CUSTOMERS: ca. 170 (65% flex vs. 35% fixed) BY NUMBER OF CUSTOMERS BY REVENUE CONTRIBUTION • 10% commercial labs • 30% commercial labs • 90% hospital labs • 70% hospital labs LIAISON PLEX COMMERCIAL LAUNCH UPDATE: • Commercial team fully established

  11. Slide 11: Q3'26 & 9M'26 LTG Revenue Variances At Constant Exchange Rates 2025

    Q3’26 & 9M’26 LTG Revenue Variances At Constant Exchange Rates 2025 Q3’26 revenues (figures in €/million) 9M’26 revenues (figures in €/million) Life Science clients: • Improving market conditions in particular in the research environment in the US Diagnostics clients: • In line with 2025 on a 9 mont

  12. Slide 12: Q3'26 & 9M'26 Profitability Profile

    Q3’26 & 9M’26 Profitability Profile Net Revenues and Adj. EBITDA data @ current exchange rates; Adj. EBITDA Margin @ constant exchange rates. 32% 34% 280 308 89 103 Net Revenues In Q3 2026, the ratio to revenues stood at 34% at constant exchange rates, and 33% at current exchange rates confirming th

  13. Slide 13: FY 2026 Company Guidance and 2026 Outlook

    FY 2026 COMPANY GUIDANCE AND 2026 OUTLOOK

  14. Slide 14: FY'26 Guidance Confirmed

    FY’26 Guidance Confirmed FY’26 GUIDANCE (@CER 2025) Revenues : Between +5% and +6% Adjust ed 1 EBITDA 2 Margin : approx. 32% - 33% CERPY Spot EUR/USD FX: 1.05 Avg. Expected 2026 EUR/USD FX: 1.18 (Source: Bloomberg) as of May 7, 2026 1 cent of difference between EUR and USD over 12 months has an impa

  15. Slide 15: FY'26 Top Line Guidance @CER2025

    FY’26 Top Line Guidance @CER2025 Revenue Guidance FY’26 Between +5% and +6% 1,195 €/mln • LTG: diagnostic customers are expected to grow at a LSD-to-MSD% rate, +LSD% offsetting the continued weakness in the Life Science business. LTG 165 €/mln • Molecular Diagnostics: growth driven by the launch of

  16. Slide 16: FY'26 Growth Trajectory by Quarter

    FY’26 Growth Trajectory by Quarter 1Q26 2Q26 3Q26 4Q26 • Immunodiagnostics: steady growth across different quarters in FY’26 as a result of the unique specialty menu and the hospital strategy, partially compensated by the normalization of volumes in Europe, with the exception of some tough compariso

  17. Slide 17: Financial Schemes

    FINANCIAL SCHEMES | 6) Diasorin

  18. Slide 18: Income Statement

    Income Statement Q3 Change 9 months Change Amounts in millions of euros 2025 2026 amount % 2025 2026 amount % Net Revenues 280.4 308.0 +28 +10% 899.7 909.6 +10 +1% Cost of sales (99.4) (110.6) -11 +11% (312.8) (322.8) -10 +3% Gross profit 181.0 197.4 +16 +9% 586.9 586.8 -0 -0% 65% 64% -45 bps 65% 65

  19. Slide 19: Balance Sheet

    Balance Sheet Amounts in millions of euros 12/31/2025 30/09/2026 Change Goodwill and intangibles assets 1,790.0 1,828.7 +39 Property, plant and equipment 255.9 274.9 +19 Other non-current assets 42.3 41.6 -1 Net working capital 325.2 371.1 +46 Other non-current liabilities (256.6) (267.9) -11 Net In

  20. Slide 20: Cash Flow Statement

    Cash Flow Statement Q3 9 months Amounts in millions of euros 2025 2026 2025 2026 Cash and cash equivalents at the beginning of the period 173.1 120.8 344.3 165.8 Cash provided by operating activities 114.6 96.5 259.6 205.8 Cash provided/(used) in investing activities (80.1) (28.7) (107.8) (41.6) Cas

  21. Slide 21: September 2026 Reconciliation to Consolidated Financial Statements

    September 2026 Reconciliation to Consolidated Financial Statements Amounbts in millions of euros Gross Profit EBITDA EBIT Net Result Financial Statements Measures 587 288 192 126 % on Revenues 65% 32% 21% 14% Adjustments “One-off” costs related to non recurring events 1 9 8 8 Depreciation of Luminex

  22. Slide 22: Slide 22

Diasorin — Q3 2026 Earnings Presentation on 6ix